Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Journal of the American Geriatrics Society|January 28, 2026
The Role of Geriatric Syndromes in Kidney Transplant Decision-Making: A Domain-Based Analysis of Comprehensive Geriatric Assessment in Older AdultsKo Harada, Yihan Wang, Yuka Shichijo, et al.
Cancer|August 12, 2006
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experienceApostolia-Maria Tsimberidou, Susan O'Brien, Hagop M Kantarjian, et al.
British Journal of Haematology|March 8, 2007
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictorsGautam Borthakur, Susan O'Brien, William G Wierda, et al.
British Journal of Haematology|March 8, 2008
Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patientsConstantine S Tam, Joselle Otero-Palacios, Lynne V Abruzzo, et al.
Blood|April 16, 2008
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaConstantine S Tam, Susan O'Brien, William Wierda, et al.
Cancer|June 16, 2004
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemiaApostolia M Tsimberidou, Michael J Keating, Francis J Giles, et al.
Clinical Transplantation|October 5, 2019
Different outcomes after kidney transplantation between African Americans and Whites: A matter of income? A single-center studyAntonios Arvelakis, Susan Lerner, Vikram Wadhera, et al.
Blood|January 20, 2011
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLLXavier C Badoux, Michael J Keating, Xuemei Wang, et al.
Cancer|August 12, 2003
Phase II study of alemtuzumab in chronic lymphoproliferative disordersAlessandra Ferrajoli, Susan M O'Brien, Jorge E Cortes, et al.
Blood|June 15, 2011
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemiaXavier C Badoux, Michael J Keating, Xuemei Wang, et al.
Pageof 7